

Table S1 Definitions and data sources for collected variables

Variable category	Variable name	Definition/criterion	Data source	Time point of assessment/ measurement
Demographics	Age	Age at initiation of first mFOLFIRINOX cycle	EMR, Admission record	Baseline
	Sex	Male/Female	EMR, Admission record	Baseline
	Smoking history	Ever smoked vs. never smoked	EMR, Medical history	Baseline
	Alcohol drinking history	Ever drank vs. never drank	EMR, Medical history	Baseline
Clinical	BMI	Weight/Height	EMR, Nursing record	Baseline
	Comorbidities	e.g., hypertension, diabetes mellitus	EMR, Medical history/ Problem list	Baseline
	PS	ECOG PS (0, 1, 2)	EMR, physician's note	Baseline
	Tumor stage	AJCC 8 th Edition (III or IV)	EMR, pathology/Imaging report	Baseline
	Prior therapies	e.g., prior surgery, systemic therapy	EMR, Medical history	Baseline
Laboratory	Hb, WBC, PLT, Cr, ALT, AST, TBIL	Standard hematologic and biochemical parameters	EMR, laboratory information system	The most recent value within 7 days before the first cycle of mFOLFIRINOX
Exposure	Oxaliplatin type	NCDP-procured vs. non-NCDP	HPPR/EMR, medication order	Throughout treatment period
Efficacy outcomes	ORR, PFS	Assessed per RECIST v1.1 criteria	EMR, radiology reports	CT/MRI scans performed every 8–12 weeks (± 2 weeks)
Safety outcomes	ADRs	All grades and grade ≥ 3 , per CTCAE v5.0	EMR, physician's and nurse's notes, laboratory reports	Continuously monitored and documented until 30 days after the last dose

ADR, adverse drug reaction; AJCC, American Joint Committee on Cancer; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; Cr, creatinine; CT, computed tomography; CTCAE, Common Terminology Criteria for Adverse Events; ECOG PS, Eastern Cooperative Oncology Group performance status; EMR, electronic medical record; Hb, hemoglobin; HPPR, hospital pharmacy procurement records; MRI, magnetic resonance imaging; NCDP, national centralized drug procurement; ORR, objective response rate; PFS, progression-free survival; PLT, platelet count; RECIST, Response Evaluation Criteria in Solid Tumors; TBIL, total bilirubin; WBC, white blood cell count.